Arafeh Rand, Shibue Tsukasa, Dempster Joshua M, Hahn William C, Vazquez Francisca
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Nat Rev Cancer. 2025 Jan;25(1):59-73. doi: 10.1038/s41568-024-00763-x. Epub 2024 Oct 28.
Despite tremendous progress in the past decade, the complex and heterogeneous nature of cancer complicates efforts to identify new therapies and therapeutic combinations that achieve durable responses in most patients. Further advances in cancer therapy will rely, in part, on the development of targeted therapeutics matched with the genetic and molecular characteristics of cancer. The Cancer Dependency Map (DepMap) is a large-scale data repository and research platform, aiming to systematically reveal the landscape of cancer vulnerabilities in thousands of genetically and molecularly annotated cancer models. DepMap is used routinely by cancer researchers and translational scientists and has facilitated the identification of several novel and selective therapeutic strategies for multiple cancer types that are being tested in the clinic. However, it is also clear that the current version of DepMap is not yet comprehensive. In this Perspective, we review (1) the impact and current uses of DepMap, (2) the opportunities to enhance DepMap to overcome its current limitations, and (3) the ongoing efforts to further improve and expand DepMap.
尽管在过去十年中取得了巨大进展，但癌症的复杂性和异质性使得识别能在大多数患者中实现持久反应的新疗法和治疗组合变得复杂。癌症治疗的进一步进展将部分依赖于与癌症的基因和分子特征相匹配的靶向治疗药物的开发。癌症依赖性图谱（DepMap）是一个大规模的数据存储库和研究平台，旨在系统地揭示数千个经过基因和分子注释的癌症模型中的癌症脆弱性情况。DepMap被癌症研究人员和转化科学家常规使用，并促进了针对多种癌症类型的几种新型和选择性治疗策略的识别，这些策略正在临床试验中进行测试。然而，目前版本的DepMap尚不全面这一点也很明显。在这篇观点文章中，我们回顾了：（1）DepMap的影响和当前用途；（2）增强DepMap以克服其当前局限性的机会；以及（3）进一步改进和扩展DepMap的正在进行的工作。
